Clinical trialObsRecruiting
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
Prognostic and Predictive Markers of Treatment Response in Patients With Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Recruiting
- Study type
- Observational
- Start
- 1 January 2003
- Expected end
- 31 December 2031
- Enrollment
- 4,050 participants
- Sites
- 15
- Primary outcomes
- Overall Survival (OS) rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 March 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Detailed description public domain (ClinicalTrials.gov)
The modest efficacy of current therapies for pancreatic cancer calls for the development of prognostic factors to guide patient selection and clinical decision-making based on tumor aggressiveness and risk of death. The aim of this study is to identify prognostic and predictive factors of response to treatments administered in pancreatic adenocarcinoma, based on a multicenter cohort established on a population derived from current clinical practice. By accurately stratifying patients according to their estimated survival, prognostic tools could aid therapeutic decisions and optimize patient selection in future clinical trials.